Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
23Andme Holding Co (ME)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/28/2025: ME (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -43.14% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 13.34M USD | Price to earnings Ratio - | 1Y Target Price 2.08 |
Price to earnings Ratio - | 1Y Target Price 2.08 | ||
Volume (30-day avg) 7774829 | Beta 1.2 | 52 Weeks Range 0.53 - 12.76 | Updated Date 04/2/2025 |
52 Weeks Range 0.53 - 12.76 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -17.39 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -186.98% | Operating Margin (TTM) -41.87% |
Management Effectiveness
Return on Assets (TTM) -33.18% | Return on Equity (TTM) -193.76% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2923778 | Price to Sales(TTM) 0.06 |
Enterprise Value 2923778 | Price to Sales(TTM) 0.06 | ||
Enterprise Value to Revenue 0.01 | Enterprise Value to EBITDA -0.17 | Shares Outstanding 19721800 | Shares Floating 16100962 |
Shares Outstanding 19721800 | Shares Floating 16100962 | ||
Percent Insiders 17.27 | Percent Institutions 26.07 |
Analyst Ratings
Rating - | Target Price 40 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
23Andme Holding Co
Company Overview
History and Background
23andMe Holding Co. was founded in 2006 by Anne Wojcicki, Linda Avey, and Paul Cusenza. Initially focused on providing ancestry information and genetic health risk reports directly to consumers, it has evolved to include therapeutic development.
Core Business Areas
- Consumer Services: Provides direct-to-consumer (DTC) genetic testing kits and related services, including ancestry reports, health predispositions, and wellness insights.
- Therapeutics: Focuses on discovering and developing novel therapies based on human genetics, leveraging the company's vast genetic database.
- Research Services: Provides genetic data and research tools to academic and pharmaceutical researchers to advance scientific understanding and drug discovery.
Leadership and Structure
Anne Wojcicki is the CEO. The organizational structure is divided into business units focusing on consumer genetics, therapeutics, and research. A Board of Directors oversees strategic direction.
Top Products and Market Share
Key Offerings
- Health + Ancestry Service: Provides reports on ancestry composition, traits, and health predispositions. Market share is estimated to be around 25% of the DTC genetic testing market. Competitors include AncestryDNA (Ancestry.com), MyHeritage DNA, and Living DNA.
- Therapeutics Pipeline: Developing novel therapies targeting specific diseases based on genetic insights. The pipeline is early-stage, making revenue contribution minimal currently. Competitors include major pharmaceutical companies and biotech firms such as Amgen (AMGN), Biogen (BIIB), and Eli Lilly (LLY).
- 23andMe+ Membership: Premium subscription service with advanced health reports, pharmacogenomics, and priority customer support. Revenue from this product contributes to ongoing subscription revenues and user retention. Competitors include other subscription-based health and wellness services.
Market Dynamics
Industry Overview
The genetic testing market is experiencing growth, driven by increased awareness of personalized medicine and advancements in genomics technology. However, regulatory scrutiny and privacy concerns remain key challenges.
Positioning
23andMe is positioned as a leader in the DTC genetic testing market, with a strong brand recognition and a large database of genetic information. Its expansion into therapeutics is intended to leverage this asset.
Total Addressable Market (TAM)
The global genetic testing market is estimated to be worth approximately $25 billion. 23andMe's positioning in the DTC market allows it to capture a substantial portion of the consumer-driven segment, while its therapeutics initiatives target a much larger pharmaceutical market.
Upturn SWOT Analysis
Strengths
- Large genetic database
- Strong brand recognition
- Pioneering role in DTC genetic testing
- Expansion into therapeutics
Weaknesses
- Data privacy concerns
- Regulatory uncertainty
- Limited profitability
- Early-stage therapeutics pipeline
Opportunities
- Partnerships with pharmaceutical companies
- Expansion into new markets
- Development of novel therapies
- Increased adoption of personalized medicine
Threats
- Increased competition
- Data breaches
- Changing regulatory landscape
- Public perception of genetic testing
Competitors and Market Share
Key Competitors
- ANCE
- MYGN
- ILMN
Competitive Landscape
23andMe has a strong brand in DTC genetic testing but faces competition from larger companies with more resources and established market presence. Its therapeutics pipeline is still early stage compared to established pharmaceutical companies.
Major Acquisitions
Lemonaid Health
- Year: 2021
- Acquisition Price (USD millions): 400
- Strategic Rationale: Expanded access to telemedicine and prescription services for personalized healthcare.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by increased adoption of DTC genetic testing services.
Future Projections: Future growth is projected to be driven by expansion into new markets and the development of novel therapies.
Recent Initiatives: Recent strategic initiatives include partnerships with pharmaceutical companies and expansion into new therapeutic areas.
Summary
23andMe has a strong brand and large database in the DTC genetic testing market. While its expansion into therapeutics presents significant opportunities for long-term growth, profitability remains a challenge due to high operating costs and regulatory hurdles. Investors should monitor the progress of its therapeutics pipeline and its ability to navigate data privacy and regulatory concerns. The Company is not profitable but is well financed.
Similar Companies
CVS
CVS Health Corp
CVS
CVS Health Corp
ILMN
Illumina Inc
ILMN
Illumina Inc
MYGN
Myriad Genetics Inc
MYGN
Myriad Genetics Inc
WBA
Walgreens Boots Alliance Inc
WBA
Walgreens Boots Alliance Inc
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Publications
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share estimates are approximate and may vary. Financial data is based on publicly available information and may not be entirely accurate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About 23Andme Holding Co
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2020-11-23 | Interim CEO, Chief Financial & Accounting Officer Mr. Joseph Selsavage | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 560 | Website https://www.23andme.com |
Full time employees 560 | Website https://www.23andme.com | ||
23andMe Holding Co. operates as a consumer genetics testing company in the United States, the United Kingdom, Canada, and internationally. The company operates in two segments, Consumer and Research Services, and Therapeutics. The Consumer and Research Services segment provides personal genome service (PGS) that consists of a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the development of novel therapies; and research and development of programs in various therapeutic areas, such as oncology, immunological and inflammatory diseases, and other disease areas, as well as engages in the out-licensing of intellectual property associated with identified drug targets and expenses related to the discovery and development of therapeutic product candidates. This segment also comprises a therapeutics product portfolio, including 23ME-00610 (P006), a humanized monoclonal antibody that interfere with the ability of CD200R1 to interact with CD200 in cancer cells; GSK6097608, an immuno-oncology program for targeting CD96; and 23ME-01473 is an immuno-oncology antibody program that targets the ULBP6 proteins in the NKG2D pathway. The company has collaboration with Mirador Therapeutics to advance mirador's precision medicines for immunology and inflammation. 23andMe Holding Co. was founded in 2006 and is headquartered in South San Francisco, California. On March 23, 2025, 23andMe Holding Co., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Eastern District of Missouri.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.